Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.

In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.

Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.

Genmab is the latest company to join an escalating arms race in antibody-drug conjugates, challenging AbbVie’s lead in ovarian cancer treatment.